James P. Buteau
305 Grattan Street
Melbourne, VIC 3000, Australia
Melbourne, VIC 3000, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 56 publications
Radioligand Therapy for Prostate Cancer - A Clinical Consultation Guide.
Journal: European urology focus
Published: May 30, 2026
Optimizing Care for Patients With Metastatic Castration-Resistant Prostate Cancer.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 07, 2026
Radionuclide Combination Strategies in Prostate Cancer: Insights from the AlphaBet Trial.
Journal: European urology focus
Published: April 28, 2026
Avoiding Prostate Biopsy in Early Prostate Cancer Detection: From Liquid Biopsy to PSMA-PET.
Journal: European urology focus
Published: April 27, 2026
From salvage to spotlight: how 2025 transformed PSMA radioligand therapy.
Journal: BJU international
Published: April 14, 2026
Prognostic Value of Restaging [18F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Therapy.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: March 16, 2026
Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.
Journal: The Lancet. Oncology
Published: February 13, 2026
Thrombotic Microangiopathy in Patients Treated with 177Lu-PSMA Combination Therapies.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: January 12, 2026
First Images on a Next-Generation Extended-Field-of-View Digital Bismuth Germanium Oxide Total-Body PET/CT.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: December 27, 2025
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 01, 2025
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.
Journal: The Lancet. Oncology
Published: October 07, 2025
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial.
Journal: The Lancet. Oncology
Published: August 07, 2025
Last Updated: 09/26/2026